Progress in the application of dupilumab for non-atopic dermatitis
SHI Xiwu
LIU Qing
WANG Xiuli
HAN Yang
HU Zhulin
Abstract：Dupilumab inhibits Th2-mediated inflammatory responses by specifically blocking the signaling pathways of interleukin-4 and interleukin-13.Recently,in addition to its approved indication for the treatment of moderate-to-severe atopic dermatitis,dupilumab has also shown effi-cacy in treating other inflammatory skin diseases,such as prurigo nodularis,bullous pemphigoid,chronic spontaneous urticaria,allergic contact dermatitis,nummular eczema,chronic hand ecze-ma,chronic actinic dermatitis,lichen amyloidosis,chronic pruritus,cutaneous immune-related adverse events,eosinophilic pustular folliculitis,alopecia areata,keloids,and some genetic skin diseases.This article reviews the progress of dupilumab in the treatment of non-atopic dermatitis skin diseases to provide more theoretical basis and treatment options for the clinicians.
Keywords：inflammatory skin diseasesdupilumabinterleukin-4interleukin-13
Publication Date：2026-01-28
Online Publishing Date：2026-03-11(First online date of this platform, not the publication date of the document)
Pages：10( 72-80,封3 )